Antinuclear Antibody Test Market value was worth USD 1169.4 million in 2019 and expected to reach USD 2109.5 million by 2024 at a CAGR of 12.52%.
The market is showcasing evident potential in the mentioned forecasting period. The antinuclear antibody test is a primary test to check a person’s autoimmune disorders. Autoimmune disorders can affect many tissues and organs in the body. This test is most often used to diagnose the Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis.
Drivers and Restraints:
Factors such as an increase in the prevalence of autoimmune diseases, such as rheumatoid arthritis and SLE, and growth in the awareness of people about these diseases, are driving this market. Autoimmune diseases can also cause type I diabetes. According to WHO, from 1980 to 2014 number of people suffering from diabetes has increased from 108 million to 422 million and is expected to grow at the same rate in near future. Other factors such as, increase in healthcare expenditure of people due to growing economies, and government healthcare insurance & reimbursement policies are fuelling this market. On the other hand, factors such as diagnostic errors, product approval, and unavailability of skilled labour are hindering the growth of this market.
Market Size Available
2018 – 2024
2019 – 2024
By Disease, By Technique, By Product, By End User
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Zeus Scientific Inc., Inova Diagnostics, Immuno Concepts, Euroimmun AG, Antibodies Inc., Thermo Fisher Scientific inc., Trinity Biotech plc, ERBA Diagnostics Inc., Bio-Rad Laboratories Inc., and Alere Inc.
This research report on the Global Antinuclear Antibody Test Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Antinuclear Antibody Test Market - By Disease
On the basis of Diseases, the Rheumatoid Arthritis is expected to have the largest share in the market until the end of the forecast period due to the increased incidences of rheumatoid arthritis.
Antinuclear Antibody Test Market - By Technique
On the basis of technique, the ELISA is currently leading the market on the basis of the technique used for testing.
Antinuclear Antibody Test Market - By Product
On the basis of product, As of 2018, Assay Kits & reagents segment accounts for the largest share of the global ANA testing market. It can be because of the growth in a number of reagent rental agreements.
Antinuclear Antibody Test Market - By End-User
North America has the biggest market share mainly because of growing population and healthcare spending, and growth of people under medical insurances in the U.S. Asia-Pacific is growing at the fastest rate in this market in terms of CAGR.
Some of the major companies dominating the Global Antinuclear Antibody Test Market profiled in the report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.3 Rheumatoid Arthritis
5.1.4 Y-o-Y Growth Analysis, By Disease
5.1.5 Market Attractiveness Analysis, By Disease
5.1.6 Market Share Analysis, By Disease
5.2.5 Y-o-Y Growth Analysis, By Technique
5.2.6 Market Attractiveness Analysis, By Technique
5.2.7 Market Share Analysis, By Technique
5.3.5 Reagents & Assay Kits
5.3.6 Y-o-Y Growth Analysis, By Product
5.3.7 Market Attractiveness Analysis, By Product
5.3.8 Market Share Analysis, By Product
5.4.3 Clinical Labs
5.4.4 Y-o-Y Growth Analysis, By End-User
5.4.5 Market Attractiveness Analysis, By End-User
5.4.6 Market Share Analysis, By End-User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Disease
184.108.40.206 By Technique
220.127.116.11 By Product
18.104.22.168 By End-User
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Disease
188.8.131.52 By Technique
184.108.40.206 By Product
220.127.116.11 By End-User
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Disease
126.96.36.199 By Technique
188.8.131.52 By Product
184.108.40.206 By End-User
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Zeus Scientific Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Inova Diagnostics
8.3 Immuno Concepts
8.4 Euroimmun AG
8.5 Antibodies Inc.
8.6 Thermo Fisher Scientific Inc.
8.7 Trinity Biotech plc
8.8 ERBA Diagnostics Inc.
8.9 Bio-Rad Laboratories Inc.
8.10 Alere Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures